Daiichi Sankyo Company, Limited · TSE:4568
Daiichi Sankyo — Q1 FY2026 Earnings Presentation
38 slides from Daiichi Sankyo's earnings presentation, Jul 31, 2026
Slide 1: FY2026 Q1 Financial Results Presentation
FY2026 Q1 Financial Results Presentation DAIICHI SANKYO CO., LTD. Tomohiro Kodama CFO July 31, 2026
Slide 2: Forward-Looking Statements
Forward-Looking Statements Management strategies and plans, financial forecasts, future projections and policies, and R&D information that Daiichi Sankyo discloses in this material are all classified as Daiichi Sankyo’s future prospects. These forward-looking statements were determined by Daiichi Sa
Slide 3: Agenda
Agenda 1 FY2025 Correction of Financial Results 2 FY2026 Q1 Financial Results 3 FY2026 Forecast 4 Business Update 5 R&D Update 6 Appendix 3
Slide 4: Correction of the Consolidated Financial Results for FY2025
Correction of the Consolidated Financial Results for FY2025, Submitted to the Tokyo Stock Exchange on July 31, 2026 Consolidated Statements of PL Consolidated Statements of Financial Position (Bn JPY) (Bn JPY) Consolidated Statements of FY2025 Correction FY2025 FY2025 Correction FY2025 Consolidated
Slide 5: 5-Year Business Plan (FY2021-FY2025) Recap: Financial Targets (Updated)
5-Year Business Plan (FY2021-FY2025) Recap: Financial Targets (Updated) At the time of planning 5YBP FY2025 Revenue 1.6 Tn JPY 2.1 Tn JPY Revenue in Oncology > 600.0 Bn JPY 954.0 Bn JPY Core Operating Profit ratio before R&D 40% 40.1% ROE > 16% 16.9% DOE > 8% 8.7% Currency exchange 1 USD=105 JPY, 1
Slide 6: Agenda
Agenda 1 FY2025 Correction of Financial Results 2 FY2026 Q1 Financial Results 3 FY2026 Forecast 4 Business Update 5 R&D Update 6 Appendix 6
Slide 7: Summary
Summary FY2026 Q1 Financial Results 2026年度 第1四半期実績 Significant increase in consolidated revenue led by ENHERTU® and Revenue DATROWAY® product sales growth Operating profit decreased by 12.0% YoY due to increased expenses Operating resulting from restructuring expenses related to EU Specialty Bus
Slide 8: Overview of FY2026 Q1 Results
Overview of FY2026 Q1 Results (Bn JPY) FY2025 Q1 FY2026 Q1 Forex Impact YoY Results Results （YoY） Revenue 474.6 574.7 +21.1% 100.1 +41.9 Cost of sales *1 87.6 126.0 38.5 +12.7 CMO Compensation Fee - 1.0 1.0 Other Cost os sales 87.6 125.0 37.5 SG&A expenses *1 180.1 226.0 45.9 +10.9 DXd ADC profit s
Slide 9: Revenue
Revenue Increased by 100.1 Bn JPY (Increased by 58.2 Bn JPY excl. forex impact) (Bn JPY) Positive Factors Negative Factors FY2025 Q1 Results FY2024 Results 474.6 Japan Business Enhertu +3.5 Lixiana -4.6 Japan Business Tarlige +3.0 (incl. Innovative Pharmaceuticals, Japan Business 0.7 Datroway +1.6 V
Slide 10: Operating Profit
Operating Profit Decreased by 11.6 Bn JPY (Bn JPY) Cost of Sales FY2025 CMO compensation Fee +1.0 (Foreign Exchange Rate Fluctuations) Q1 Results FY2025 Results 96.7 Other cost of sales +37.5 (Increase in expenses related to sales expansion, Valuation Losses on related to Revenue inventories, etc.)
Slide 11: Profit Attributable to Owners of the Company
Profit Attributable to Owners of the Company Decreased by 16.9 Bn JPY (Bn JPY) FY2025 Q1 Q1Results FY2025 Results 85.5 Financial Income/Expenses etc. -2.5 (Profit decreased) • Improvement in investment securities +1.5 valuation gains/losses • Decrease in interest income -0.7 Operating • Decrease in
Slide 12: Agenda
Agenda 1 FY2025 Correction of Financial Results 2 FY2026 Q1 Financial Results 3 FY2026 Forecast 4 Business Update 5 R&D Update 6 Appendix 12
Slide 13: Revision of FY2026 Forecast
Revision of FY2026 Forecast (Bn JPY) FY2026 FY2026 vs. Forecast (As of May) (As of July) Revenue Revenue 2,280.0 2,340.0 60.0 ：Forex impact, Oncology Business Unit, EU Specialty Business Unit ：ASCA Business Unit Cost of sales *1 530.0 550.0 20.0 80.0 80.0 - Cost of Sales CMO Compensation Fee Other C
Slide 14: Agenda
Agenda 1 FY2025 Correction of Financial Results 2 FY2026 Q1 Financial Results 3 FY2026 Forecast 4 Business Update 5 R&D Update 6 Appendix 14
Slide 15: ENHERTU Performance
ENHERTU® Performance The simultaneous approvals of two indications for early-stage breast cancer enables coverage of a broad range of treatment lines, from early-stage to metastatic in the US Sales growth is driven not only by HER2+ BC 1L but also by HER2+ solid tumors in the US • The solid tumo
Slide 16: DATROWAY Performance
DATROWAY® Performance Treated approx. 7,000 patients globally since launch, approx. 1.4 times the prior quarter Robust sales growth in the US and Japan • The US sales mainly driven by lung cancer indication, and triple negative breast cancer (TNBC) is growing steadily post launch • With the appr
Slide 17: Agenda
Agenda 1 FY2025 Correction of Financial Results 2 FY2026 Q1 Financial Results 3 FY2026 Forecast 4 Business Update 5 R&D Update 6 Appendix 17
Slide 18: 5DXd ADCs Next Wave 1st BGT: DXd ADCs
Growth of DXd ADC during 5YBP (FY2026-FY2030) and Identification of Breakthrough Generating Technology (BGT) Focus on DXd ADCs including DS-3939 and DS3790 as the 1st BGT and identify Next BGTs by FY2030 ENHERTU® DATROWAY® 5DXd ADCs HER3-DXd 1st BGT: DXd ADCs I-DXd (5DXd ADCs +DS-3939 & DS3790) R-DX
Slide 19: Indication Expansion to HER2+ Early Breast Cancer
Indication Expansion to HER2+ Early Breast Cancer ENHERTU® in the Curative-Intent Setting DESTINY-Breast11/DESTINY-Breast05 Ph3 Neoadjuvant and adjuvant settings for HER2+ early breast cancer approved in US (May 2026) DESTINY-Breast11 Study (Neoadjuvant Setting) DESTINY-Breast05 Study (Adjuvant Sett
Slide 20: ENHERTU Regulatory Updates
ENHERTU® Regulatory Updates Achieved approval for HER2 positive tumors across all three major regions (US, Japan, and EU) May 2026: HER2 positive solid tumors − Received positive CHMP opinion (DESTINY-PanTumor02 etc.) Jun 2026: − Approved*1 in EU Approved in US (Apr 2024)*1 and Japan (Mar 2026)*2.
Slide 21: DATROWAY New Indication Approval for 1L metastatic TNBC in US
DATROWAY® New Indication Approval for 1L metastatic TNBC in US TROPION-Breast02 Ph3 US approval granted for patients with metastatic or unresectable TNBC who are not candidates for PD-1/PD-L1 inhibitor therapy in May 2026 Main studies in Breast Cancer Field Datroway® improved mPFS by 5.3 months an
Slide 22: DATROWAY Targeting Unmet Needs in Muscle-Invasive Urothelial Carcinoma
Targeting Unmet Needs in Muscle-Invasive Urothelial DATROWAY® Carcinoma with combination therapy TROPION-Urothelial04 Ph3 Ph3 study to investigate Datroway® and rilvegostomig as adjuvant therapy in MIUC to be initiated in FY2026 H2 Study Design Significant unmet medical need remains for Eligible P
Slide 23: DS1025 Novel Regulatory T (Treg) Cell-Directed ADC
DS1025 Novel Regulatory T (Treg) Cell-Directed ADC DS1025 is an CD25-directed ADC designed to deplete immunosuppressive Treg cells in the tumor microenvironment and enhance anti-tumor immunity Mechanism of Action Anti-CD25 ADC building on Daiichi Sankyo DXd ADC technology with an IO- optimized cyt
Slide 24: Next Wave Regulatory Updates
Next Wave Regulatory Updates New assets approved in Japan and China MIMRIT® (MMR vaccine) May 2026: Prevention of measles, mumps and rubella — Approved in Japan VANFLYTA® (quizartinib, FLT3 inhibitor) Jun 2026: FLT3-ITD positive AML, 1L — Approved in China QuANTUM-First AML: acute myeloid leukemia,
Slide 25: FY2026 News Flow
FY2026 News Flow As of Jul 2026 Upcoming regulatory decisions Planned major data disclosures DESTINY-Breast09: HER2 positive BC, 1L, Ph3 European Society For Medical Oncology（ESMO, Oct 23-27, 2026） ENHERTU® (pertuzumab combo) • EU: FY2026 H1 HERTHENA-PanTumor01: solid tumors, Ph2 TROPION-Breast02: T
Slide 26: Q&A
Q&A Tomohiro Kodama Akihiro Inoguchi Ken Keller CFO Head of Development Function Head of Global Oncology Business 26
Slide 27: Agenda
Agenda 1 FY2025 Correction of Financial Results 2 FY2026 Q1 Financial Results 3 FY2026 Forecast 4 Business Update 5 R&D Update 6 Appendix 27
Slide 28: Revenue: Business Units (incl. Forex Impact)
Revenue: Business Units (incl. Forex Impact) (Bn JPY) FY2025 Q1 FY2026 Q1 YoY Results Results Japan Business 125.0 120.0 -4.9 Daiichi Sankyo Healthcare 20.9 22.6 +1.6 Oncolgy Business 131.2 197.4 +66.2 Enhertu 124.6 176.9 +52.3 Datroway 3.1 16.6 +13.4 Turalio 1.6 1.0 -0.6 Vanflyta 1.9 2.9 +1.1 Ameri
Slide 29: Revenue: Major Products in Japan
Revenue: Major Products in Japan (Bn JPY) FY2025 Q1 FY2026 Q1 YoY Results Results Lixiana anticoagulant 37.7 33.0 -4.6 Tarlige pain treatment 16.5 19.5 +3.0 Treatment for osteoporosis/ inhibitor of the progression Pralia of bone erosion associated with rheumatoid arthritis 12.4 12.9 +0.5 anti-cancer
Slide 30: 5DXd ADCs Revenue (incl. Forex Impact)
5DXd ADCs Revenue (incl. Forex Impact) ( Bn JPY) FY2026 Q1 FY2026 vs May. YoY Results Forecast(As of Jul.) Forecast ENHERTU® 239.8 +78.8 1,030.0 +36.6 Product Sales 219.2 +64.0 894.9 +33.6 Upfront and Milestone Payments, etc. 20.6 +14.8 135.1 +3.1 DATROWAY® 23.9 +15.3 127.2 +5.7 Product Sales 20.6 +
Slide 31: 5DXd ADCs Upfront and Milestone Payments
5DXd ADCs Upfront and Milestone Payments (Bn JPY) FY2026 Q1 FY2026 Forecast vs May Total Consideration Asset Item YoY Results (As of Jul) Forecast (as of Jun 2026) Upfront Payment 2.6 - 10.2 - 149.0 ® Regulatory Milestones 17.8 +14.8 30.0 +3.1 238.6 ENHERTU Quid Related Payment 0.3 - 1.2 - 17.2 Sale
Slide 32: Major R&D Milestones: ENHERTU
Major R&D Milestones : ENHERTU® As of Jul 2026 Target indication FY2026 Project FY2027 [phase, study name] H1 H2 • HER2+ with residual invasive disease following • Approved (US) neoadjuvant, adjuvant [Ph3, DESTINY-Breast05] • Filing accepted (CN) • Regulatory decision • HER2+, 1L, mono or pertuzumab
Slide 33: Major R&D Milestones: DATROWAY
Major R&D Milestones : DATROWAY® As of Jul 2026 Target indication FY2026 Project FY2027 [phase, study name] H1 H2 • Non-squamous, w/o AGA, PD-L1 TPS <50%, 1L, pembrolizumab ± PBC combo • TLR anticipated [Ph3, TROPION-Lung07] • Non-squamous, w/o AGA, PD-L1 TPS ≥50%, 1L, pembrolizumab combo • TLR anti
Slide 34: Major R&D Milestones: I-DXd and Next Wave
Major R&D Milestones : I-DXd and Next Wave As of Jul 2026 Target indication FY2026 Project FY2027 [phase, study name] H1 H2 • Regulatory decision • ES-SCLC, 2L+ [Ph2, IDeate-Lung01] • Filing accepted (US) anticipated (US) I-DXd • ES-SCLC, 2L [Ph3, IDeate-Lung02] • TLR anticipated • FLT3-ITD positive
Slide 35: Major R&D Pipeline: 5DXd ADCs (1)
Major R&D Pipeline: 5DXd ADCs (1) As of Jul 2026 Phase 1 Phase 1/2 Phase 2 (US/EU/Asia) HER2 low BC (JP/US/EU/Asia) NSCLC (US/EU/Asia) HER2+ BC 2L+/1L (TBA) in prep HR+/HER2 low or HER2 (JP/US/EU/Asia) solid tumors (US/EU/Asia) non-squamous NSCLC 2L chemo naïve/post chemo （combo) (combo) ultralow BC
Slide 36: Major R&D Pipeline: 5DXd ADCs (2)
Major R&D Pipeline: 5DXd ADCs (2) As of Jul 2026 Phase 2/3 Phase 3 Regulatory phase (JP/US/EU/Asia) UC post enfortumab vedotin (JP/US/EU/Asia) HER2+ BC 1L (JP/US/EU/Asia) HER2 expressing pMMR EC (JP/US/EU/Asia) TROP2 NMR+ (JP/US/EU/Asia) HR positive and HER2 (JP/EU/CN) HER2+ BC with residual invasiv
Slide 37: Major R&D Pipeline: Next Wave
Major R&D Pipeline: Next Wave As of Jul 2026 Phase 1 Phase 1/2 Phase 2 Phase 3 DS-1103 (US/EU) DS-3939 (JP/US/EU/Asia) EZHARMIA® (EU) VANFLYTA® (JP/US/EU/Asia) Anti-SIRPα antibody TA-MUC1-directed DXd ADC EZH1/2 inhibitor FLT3 inhibitor HER2-altered solid tumors (ENHERTU® combo) Solid tumors BCL FLT
Slide 38: Contact
Contact Daiichi Sankyo Co., Ltd. Investor Relations and Shareholder Relations Department Email: DaiichiSankyoIR_jp@daiichisankyo.com
Daiichi Sankyo Company — Q1 FY2026 Earnings Presentation on 6ix